16-dehydropregnenolone | 104010-41-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 16-dehydropregnenolone
• 英文别名: 3-Hydroxypregna-5,16-dien-20-one；1-[(8R,9S,10R,13S,14S)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone
• CAS: 104010-41-5
• 化学式: C₂₁H₃₀O₂
• 分子量: 314.468
• InChiKey: YLFRRPUBVUAHSR-SRJGTTDWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.76
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  16-dehydropregnenolone 在 2,2,6,6-四甲基哌啶氧化物 、 氧气 、 ferric nitrate 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 以100%的产率得到16-去氢黄体酮
  参考文献：
  名称：

  一种甾体3-酮-4-烯物合成工艺

  摘要：

  本专利公开了一种甾体3‑酮‑4‑烯物的合成新工艺。该方法是以甾体3‑羟基‑5烯物为起始物，在非质子性有机溶剂中，以空气或氧气为氧化剂，以过渡金属硝酸盐和2,2,6,6‑四甲基哌啶‑1‑氧自由基或其类似物作为催化剂，氧化得到甾体3‑酮‑4‑烯物。该方法产率高，反应条件温和，操作易于控制，耗能低，成本低，安全，整个过程对环境友好，适合工业化。

  公开号：

  CN105622712B
• 作为产物：
  描述：

  2-萘乙腈 以96的产率得到16-dehydropregnenolone
  参考文献：
  名称：

  Eur. J. Med. Chem. 2011, 46, 3681-3689

  摘要：

  DOI：

文献信息

• Steroids useful as anti-cancer, anti-obesity, anti-hyperglycemic, anti-autoimmune and anti-hyper-cholesterolemic agents
  申请人：Research Corporation

  公开号：EP0210665A1

  公开（公告）日：1987-02-04

  This invention relates to novel compounds of the formula: Y is lower alkyi; and X and Z are independently hydrogen, halogen. lower alkyl or hydroxy, or X and Z taken together are hydroxy-imino with the proviso that when Y is methyl and Z is hydrogen. X is other than methyl or hydroxy and with the further proviso that X and Z are not both hyorogen.

  本发明涉及式中的新型化合物： Y 是低级烷基；和 X 和 Z 独立地为氢、卤素、低级烷基或羟基，或 X 和 Z 合在一起为羟基亚氨基，但条件是当 Y 为甲基和 Z 为氢时，X 不是甲基或羟基。X不是甲基或羟基，而且X和Z不能都是次卤素。
• Erasable image forming material
  申请人：KABUSHIKI KAISHA TOSHIBA

  公开号：EP0980028A1

  公开（公告）日：2000-02-16

  An erasable image forming material includes a color former, a developer, a binder resin, and a polymer decolorizer having an electron donating group capable of physically or chemically adsorbing the developer. This polymer decolorizer is, e.g., a polymer compound having a sugar skeleton, representatively starch. This image forming material can form sharp images and erase images by heat or a solvent to achieve a good erased state.

  一种可擦除图像形成材料包括显色剂、粘合剂树脂和聚合物脱色剂，聚合物脱色剂具有电子捐赠基团，能以物理或化学方式吸附显色剂。聚合物脱色剂可以是具有糖骨架的聚合物化合物，例如淀粉。这种图像形成材料可以形成清晰的图像，并通过加热或溶剂擦除图像，以达到良好的擦除状态。
• Medicaments for hypolipidemic and hypoglycemic conditions
  申请人：Council of Scientific and Industrial Research

  公开号：EP1020191A1

  公开（公告）日：2000-07-19

  The invention provides a method of using pregnadienones and pregnadienols represented by the structural formula (I) as shown herein below Wherein X=OH or O or combination thereof and positioning of olefinic bonds are at 4(5); 5(6); 6(17); 17(20) or various combinations and said compounds containing at least one olefinic bond in or on their D-ring for the treatment of hypolipidemic and hypoglycemic conditions in mammals, said method comprising administering an effective amount of the said compounds to the recipient mammals.

  本发明提供了一种使用下述结构式（I）所代表的孕二烯酮和孕二烯醇的方法 其中X=OH或O或其组合，烯烃键的定位为4(5)；5(6)；6(17)；17(20)或各种组合，且所述化合物在其D环中或D环上含有至少一个烯烃键，用于治疗哺乳动物的降脂和降糖病症，所述方法包括向受体哺乳动物施用有效量的所述化合物。
• Decolorable image forming material and decoloring method of the same
  申请人：Kabushiki Kaisha Toshiba

  公开号：EP1041447A1

  公开（公告）日：2000-10-04

  A decolorable image forming material containing a color former, a developer and a binder resin, in which the binder resin has a property that it is compatible with the color former when the material is in contact with a solvent and that it keeps the compatible state when the solvent is removed, or has a property that it shifts an equilibrium between the color former and the developer to a non-developed side when the temperature of the material is raised and that it keeps the state shifted to the non-developed side when the temperature of the material is lowered.

  一种含有显色剂、显影剂和粘合剂树脂的可脱色图像形成材料，其中粘合剂树脂具有以下特性：当材料与溶剂接触时，粘合剂树脂与显色剂相容；当溶剂移除时，粘合剂树脂保持相容状态；或者具有以下特性：当材料温度升高时，粘合剂树脂将显色剂与显影剂之间的平衡状态转移到非显影侧；当材料温度降低时，粘合剂树脂保持转移到非显影侧的状态。
• Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
  申请人：INSERM (Institut National de la Santé et de la Recherche Médicale)

  公开号：EP1886685A1

  公开（公告）日：2008-02-13

  The present invention relates to uses, methods and compositions for modulating replication of viruses of the Flaviviridae family, such as hepatitis C virus, through the farnesoid X receptor (FXR) activation or inhibition. More specifically, the invention relates to the use of an antagonist of FXR or an inhibitor of expression thereof for the manufacture of a medicament intended for treating a Flaviviridae virus infection in a subject in need thereof. The invention encompasses the use of antagonists of FXR, such as guggulsterone, or use of inhibitors of FXR expression. The invention relates also to a cell culture system allowing the replication of HCV and to methods for diagnosing HCV infection, screening of anti-viral compounds and vaccine or viral protein production.

  本发明涉及通过法尼类固醇 X 受体（FXR）激活或抑制来调节黄病毒科病毒（如丙型肝炎病毒）复制的用途、方法和组合物。更具体地说，本发明涉及使用 FXR 的拮抗剂或其表达抑制剂来制造用于治疗有需要的受试者的 Flaviviridae 病毒感染的药物。本发明包括使用 FXR 的拮抗剂，如古格雄酮，或使用 FXR 表达抑制剂。本发明还涉及一种允许 HCV 复制的细胞培养系统，以及诊断 HCV 感染、筛选抗病毒化合物和生产疫苗或病毒蛋白的方法。